GlassScriptPhysician profile
Hillary L Bownik
NPI 1013147206
$84,645.87
in general payments reported to CMS, 2019-2025
31 companies · $23K in 2025
The $23K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $990 · 2021: $12K · 2022: $18K · 2023: $2,603 · 2024: $13K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Food and Beverage: $4,180 · Consulting Fee: $1,738 · Travel and Lodging: $1,221 · Education: $39.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,879.86 |
| Food and Beverage | $4,179.90 |
| Consulting Fee | $1,737.50 |
| Travel and Lodging | $1,220.67 |
| Education | $39.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $38,024.62 | 2019-2025 | Tremfya, Stelara, Simponi |
| Janssen Scientific Affairs, LLC | $25,872.45 | 2019-2022 | |
| Abbvie INC. | $8,224.46 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Takeda Pharmaceuticals U.S.A., INC. | $8,183.74 | 2019-2025 | Entyvio, Eohilia |
| Amgen INC. | $2,445.02 | 2021 | |
| Celgene Corporation | $263.09 | 2021-2024 | Zeposia |
| Celltrion USA INC. | $208.67 | 2023-2025 | Vegzelma, Yuflyma, Zymfentra |
| Merck Sharp & Dohme LLC | $186.45 | 2019-2024 | Dificid |
| Genzyme Corporation | $150.69 | 2022-2025 | |
| Pfizer INC. | $101.01 | 2020-2025 | |
| Lilly USA, LLC | $99.41 | 2024-2025 | Omvoh |
| Mauna Kea Technologies, INC. | $93.95 | 2019 | |
| Boston Scientific Corporation | $85.80 | 2019 | |
| Fresenius Kabi USA, LLC | $85.12 | 2023-2024 | Idacio |
| Daiichi Sankyo INC. | $76.01 | 2019-2024 | Injectafer |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $71.66 | 2024-2025 | Sucraid, Sucraid |
| Organon LLC | $65.97 | 2023-2025 | Renflexis, Hadlima |
| Phathom Pharmaceuticals, INC. | $61.21 | 2024-2025 | Voquezna |
| Amag Pharmaceuticals, INC. | $46.33 | 2021 | |
| Novo Nordisk INC | $46.06 | 2025 | Wegovy |
| Ardelyx, INC. | $40.51 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $38.84 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $34.23 | 2023 | |
| Endo Pharmaceuticals INC. | $29.56 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $24.57 | 2021 | |
| Medtronic, INC. | $20.92 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.17 | 2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.13 | 2023 | Xifaxan |
| La Jolla Pharmaceutical Company | $13.32 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $11.97 | 2022-2023 | Inflation Device |
| Endogastric Solutions, INC | $9.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hillary Bownik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.